Literature DB >> 11493009

Crystal structure of PTP-SL/PTPBR7 catalytic domain: implications for MAP kinase regulation.

S E Szedlacsek1, A R Aricescu, T A Fulga, L Renault, A J Scheidig.   

Abstract

Protein tyrosine phosphatases PTP-SL and PTPBR7 are isoforms belonging to cytosolic membrane-associated and to receptor-like PTPs (RPTPs), respectively. They represent a new family of PTPs with a major role in activation and translocation of MAP kinases. Specifically, the complex formation between PTP-SL and ERK2 involves an unusual interaction leading to the phosphorylation of PTP-SL by ERK2 at Thr253 and the inactivating dephosphorylation of ERK2 by PTP-SL. This interaction is strictly dependent upon a kinase interaction motif (KIM) (residues 224-239) situated at the N terminus of the PTP-SL catalytic domain. We report the first crystal structure of the catalytic domain for a member of this family (PTP-SL, residues 254-549, identical with residues 361-656 of PTPBR7), providing an example of an RPTP with single cytoplasmic domain, which is monomeric, having an unhindered catalytic site. In addition to the characteristic PTP-core structure, PTP-SL has an N-terminal helix, possibly orienting the KIM motif upon interaction with the target ERK2. An unusual residue in the catalytically important WPD loop promotes formation of a hydrophobically and electrostatically stabilised clamp. This could induce increased rigidity to the WPD loop and therefore reduced catalytic activity, in agreement with our kinetic measurements. A docking model based on the PTP-SL structure suggests that, in the complex with ERK2, the phosphorylation of PTP-SL should be accomplished first. The subsequent dephosphorylation of ERK2 seems to be possible only if a conformational rearrangement of the two interacting partners takes place. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493009     DOI: 10.1006/jmbi.2001.4890

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents.

Authors:  Juan José Muñoz; Céline Tárrega; Carmen Blanco-Aparicio; Rafael Pulido
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

Review 2.  Generation of inhibitor-sensitive protein tyrosine phosphatases via active-site mutations.

Authors:  Anthony C Bishop; Xin-Yu Zhang; Anna Mari Lone
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

3.  Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.

Authors:  Guang Lin; Victoria Aranda; Senthil K Muthuswamy; Nicholas K Tonks
Journal:  Genes Dev       Date:  2011-07-01       Impact factor: 11.361

4.  Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases.

Authors:  Jeyanthy Eswaran; Jens Peter von Kries; Brian Marsden; Emma Longman; Judit E Debreczeni; Emilie Ugochukwu; Andrew Turnbull; Wen Hwa Lee; Stefan Knapp; Alastair J Barr
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

5.  Structural basis of substrate recognition by hematopoietic tyrosine phosphatase.

Authors:  David A Critton; Antoni Tortajada; Geoffrey Stetson; Wolfgang Peti; Rebecca Page
Journal:  Biochemistry       Date:  2008-12-16       Impact factor: 3.162

6.  The differential regulation of p38α by the neuronal kinase interaction motif protein tyrosine phosphatases, a detailed molecular study.

Authors:  Dana May Francis; Ganesan Senthil Kumar; Dorothy Koveal; Antoni Tortajada; Rebecca Page; Wolfgang Peti
Journal:  Structure       Date:  2013-08-08       Impact factor: 5.006

7.  Interface analysis of the complex between ERK2 and PTP-SL.

Authors:  Mihaela C Balasu; Laurentiu N Spiridon; Simona Miron; Constantin T Craescu; Axel J Scheidig; Andrei-Jose Petrescu; Stefan E Szedlacsek
Journal:  PLoS One       Date:  2009-05-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.